Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372937 | 0.90 | SLC6A4 (0.52) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4375443 | 0.86 | SLC6A2 (0.48) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4370360 | 0.85 | SLC6A2 (0.48) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4369338 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4369356 | 0.81 | SLC6A4 (0.53) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4370231 | 0.80 | SLC6A2 (0.46) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4372055 | 0.80 | SLC6A2 (0.48) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4380012 | 0.79 | SLC6A4 (0.54) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4371093 | 0.79 | SLC6A2 (0.47) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4371896 | 0.77 | SLC6A2 (0.62) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322592-B2 | SUBSTITUTED 1-AMINOBUTAN-3-OL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-06-17 | — | — | EP | claimed |
| US-7022739-B2 | Substituted 1-aminobutan-3-ol compounds | GRUENENTHAL GMBH (DE) | 2006-04-04 | — | — | US | claimed |
| EP-1322592-B1 | SUBSTITUTED 1-AMINOBUTAN-3-OL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2004-07-28 | — | — | EP | claimed |
| US-20030216393-A1 | Substituted 1-aminobutan-3-ol compounds | GRUENENTHAL GMBH (DE) | 2003-11-20 | — | — | US | claimed |
| EP-1322592-A1 | SUBSTITUTED 1-AMINOBUTAN-3-OL DERIVATIVES | Grünenthal GmbH (DE) | 2003-07-02 | — | — | EP | claimed |
| WO-2002028817-A1 | SUBSTITUTED 1-AMINOBUTAN-3-OL DERIVATIVES | Grünenthal GmbH (DE) | 2002-04-11 | — | — | WO | claimed |
| EP-1322592-B2 | SUBSTITUTED 1-AMINOBUTAN-3-OL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-7022739-B2 | Substituted 1-aminobutan-3-ol compounds | GRUENENTHAL GMBH (DE) | 2006-04-04 | — | — | US | disclosed |
| EP-1322592-B1 | SUBSTITUTED 1-AMINOBUTAN-3-OL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2004-07-28 | — | — | EP | disclosed |
| US-20030216393-A1 | Substituted 1-aminobutan-3-ol compounds | GRUENENTHAL GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
| EP-1322592-A1 | SUBSTITUTED 1-AMINOBUTAN-3-OL DERIVATIVES | Grünenthal GmbH (DE) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002028817-A1 | SUBSTITUTED 1-AMINOBUTAN-3-OL DERIVATIVES | Grünenthal GmbH (DE) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216393-A1 | Substituted 1-aminobutan-3-ol compounds | CYP3A43, UGT1A3, UGT2B7 | SLC6A2 3734/4885SLC6A4 3269/4885OPRM1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.